Progress, prospects, and problems in Epstein-Barr virus vaccine development. - Wikidata - awgldk - TriplyDB

Progress, prospects, and problems in Epstein-Barr virus vaccine development.

Progress, prospects, and problems in Epstein-Barr virus vaccine development.

http://www.wikidata.org/entity/Q33812640

about

Infectious Mononucleosis Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination.Type I Interferons and NK Cells Restrict Gammaherpesvirus Lymph Node Infection.Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities.Transplantation of Solid Organ Recipients Shedding Epstein-Barr Virus DNA Pretransplant: A Prospective Study.Expression and immunogenic characterization of recombinant gp350 for developing a subunit vaccine against Epstein-Barr virus.Age-specific prevalence of Epstein-Barr virus infection among Minnesota children: effects of race/ethnicity and family environment.Computer-Aided Design of an Epitope-Based Vaccine against Epstein-Barr Virus.Gamma-herpesvirus colonization of the spleen requires lytic replication in B cells.Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.EBV based cancer prevention and therapy in nasopharyngeal carcinoma.A single epitope of Epstein-Barr Virus stimulate IgG production in mice

P2860

Q26783692-718E378A-96C8-44CD-8A3F-60D60F0364F8 Q35994831-7A565D1F-A041-4EDB-B5E6-2B4864F7DE21 Q37300475-4AAEB785-7D4C-4309-B609-FEE35E5ECC03 Q37745980-6128AE66-9C63-427D-949A-F55F183DD26D Q39170011-257E4D12-EDB5-4896-AE82-E65E3939CD13 Q40038712-1A29FB3D-909E-4A32-B014-8151A7494E65 Q40967391-610E6679-8727-48BE-8D89-4F399735EB15 Q42219174-D0E3F165-9617-46FE-A376-E58BAAB84F9B Q44549769-7B532939-821F-4754-8505-8FBE3AC933A4 Q47552272-5073E41A-38C5-4C89-9208-678FF54ADC8B Q54939538-22E3EEF9-7FB3-484E-8C33-859033921D2D Q55003883-56F46880-7D1F-46F3-8971-ED82EC42ED56 Q57191915-E66276EA-54D1-4938-A75A-430ED751EF00

P2860

Progress, prospects, and problems in Epstein-Barr virus vaccine development.

http://www.wikidata.org/entity/Q33812640

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Progress, prospects, and problems in Epstein-Barr virus vaccine development.

@ast

Progress, prospects, and problems in Epstein-Barr virus vaccine development.

@en

type

label

Progress, prospects, and problems in Epstein-Barr virus vaccine development.

@ast

Progress, prospects, and problems in Epstein-Barr virus vaccine development.

@en

prefLabel

Progress, prospects, and problems in Epstein-Barr virus vaccine development.

@ast

Progress, prospects, and problems in Epstein-Barr virus vaccine development.

@en

P1433

Q33812640-2F2997CF-F53B-4686-93D3-B4AF1371BCFA

P1476

Q33812640-0395541A-5372-4BA5-B476-472B2D4037CD

P2093

Q33812640-FD48C5A5-BE34-44A5-8A2F-26BE07F19519

P2860

Q33812640-0FFC0212-BAB7-4226-BD20-8FB5CC0BEDC2

Q33812640-1080E914-8489-46C0-9C7B-805DF66FA662

Q33812640-1A5C4A9D-7602-440C-9550-E9204E31EF2B

Q33812640-1C072206-250C-4656-B77B-3A3CE54AEBD8

Q33812640-24415244-BB1C-4D48-9583-6C1F81333DD4

Q33812640-289C7B77-B1D6-4E62-89EF-487D3A4757B4

Q33812640-35738DF9-AA16-4EEA-8994-B120551CB915

Q33812640-3F6F20A4-1B1C-412E-828D-218A0A1D55D4

Q33812640-4E8F659C-6720-4214-9BE4-0F55E05784E9

Q33812640-5253AF16-942D-4C94-A86A-04BABD245C58

P304

Q33812640-8C762B11-628B-4DE3-95DA-C001081E9AB1

P31

Q33812640-4DDF8C0C-0A64-4E6A-81DA-0C782544003B

P356

Q33812640-8DECEAEB-FF93-4E65-AEAB-3EE8CD34CFA4

P478

Q33812640-59B23850-B78C-4A66-AE10-558C8B51C498

P577

Q33812640-C6F8E454-DC76-4402-8842-A216A61FA394

P698

Q33812640-2A7ABCD8-34CE-41CC-8297-9845DCF1A466

P921

Q33812640-F6EFB56F-A16E-4441-B420-2E65CDE9CA23

P932

Q33812640-0E0FE842-9AC6-40F1-B999-D63DEFD87B3D

P356

J.COVIRO.2014.02.005

P1433

Current opinion in virology

P1476

Progress, prospects, and problems in Epstein-Barr virus vaccine development.

@en

P2093

Henry H Balfour

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis

An animal model for acute and persistent Epstein-Barr virus infection

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis.

HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma

Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults.

Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.

Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge

Smallpox vaccine: contraindications, administration, and adverse reactions.

Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay

P304

1-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.COVIRO.2014.02.005

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24632197

http://www.w3.org/2001/XMLSchema#string

P921

Epstein–Barr virus

P932

4072744

http://www.w3.org/2001/XMLSchema#string